Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems

Prospective, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Investigate the Efficacy and Safety of 10mg Memantine in the Treatment of Memory, Concentration or Attention Problems in the Absence of Dementia

In this study, memantine will be tested in a new indication: in the treatment of subjective memory, concentration, or attention problems (subjective cognitive impairment) in the absence of dementia.

Inclusion Criteria:

• Subjective worsening of memory, concentration or attention problems for longer than 6 months
• Subject can confirm that a relative or friend has noticed the memory, concentration or attention problems of the subject
• Experience of the memory, concentration or attention problems at least four times per week

Exclusion Criteria:

• Significant neurological disease or major psychiatric disorder (e.g. diagnosis of psychosis or dementia)
• Significant systemic illness, such as cancer, heart or kidney failure, uncontrolled diabetes
• History of stroke or seizure, or myocardial infarction within the last year (e.g. by inclusion questionnaire, physician interview)